Literature DB >> 15917551

In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.

Michael Green1, Coburn Allen, John Bradley, Barry Dashefsky, Janet R Gilsdorf, Mario J Marcon, Gordon E Schutze, Clay Smith, Emmanuel Walter, Judith M Martin, Kathryn A Edwards, Karen A Barbadora, Renee M Rumbaugh, Ellen R Wald.   

Abstract

In vitro susceptibility testing of 2,797 group A streptococcus (GAS) isolates demonstrated that telithromycin was fully active against all macrolide-susceptible strains and among 80 of 115 macrolide-resistant GAS expressing the M phenotype. Telithromycin resistance was identified in 2 of 45 strains expressing the inducible macrolide-lincosamide-streptogramin B phenotype and four of nine isolates expressing the constitutive macrolide-lincosamide-streptogramin B resistance phenotype.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15917551      PMCID： PMC1140514          DOI： 10.1128/AAC.49.6.2487-2489.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.

Authors:  S Cha; H Lee; K Lee; K Hwang; S Bae; Y Lee
Journal:  J Infect Chemother       Date:  2001-06       Impact factor: 2.211

2.  In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.

Authors:  Michael R Jacobs
Journal:  Clin Infect Dis       Date:  2002-08-09       Impact factor: 9.079

3.  Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.

Authors:  J Jalava; J Kataja; H Seppälä; P Huovinen
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci.

Authors:  Virginia D Shortridge; Ping Zhong; Zhensheng Cao; Jill M Beyer; Laurel S Almer; Nancy C Ramer; Stella Z Doktor; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance.

Authors:  G Cornaglia; M Ligozzi; A Mazzariol; M Valentini; G Orefici; R Fontana
Journal:  Emerg Infect Dis       Date:  1996 Oct-Dec       Impact factor: 6.883

7.  Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons.

Authors:  Robert R Tanz; Stanford T Shulman; Virginia D Shortridge; William Kabat; Kathy Kabat; Emily Cederlund; Jason Rippe; Jill Beyer; Stella Doktor; Bernard W Beall
Journal:  Clin Infect Dis       Date:  2004-11-18       Impact factor: 9.079

8.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Chun-Ming Lee; Wen-Kuei Huang; Tsu-Lan Wu; Jen-Hsien Wan; Dine Yang; Jainn-Ming Shyr; Yin-Ching Chuang; Jing-Jou Yan; Jang-Jih Lu; Jiunn-Jong Wu; Wen-Chien Ko; Feng-Yee Chang; Yi-Chueh Yang; Yeu-Jun Lau; Yung-Ching Liu; Hsieh-Shong Leu; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes.

Authors:  Jari Jalava; Martti Vaara; Pentti Huovinen
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-05-06       Impact factor: 3.944
View more
  1 in total

1.  Streptococcus pyogenes isolates with high-level macrolide resistance and reduced susceptibility to telithromycin associated with 23S rRNA mutations.

Authors:  David J Farrell; Jemma Shackcloth; Karen A Barbadora; Michael D Green
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.